TSHA
Taysha Gene Therapies Inc

2,030
Mkt Cap
$1.21B
Volume
3.31M
52W High
$5.51
52W Low
$1.05
PE Ratio
-11.45
TSHA Fundamentals
Price
$4.06
Prev Close
$4.43
Open
$4.44
50D MA
$4.38
Beta
1.61
Avg. Volume
3.92M
EPS (Annual)
-$0.357
P/B
5.08
Rev/Employee
$114,150.68
Loading...
Loading...
News
all
press releases
TSHA FY2026 EPS Forecast Raised by Cantor Fitzgerald
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2026 EPS estimates for shares of Taysha Gene Therapies in a note issued to investors...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
SG Americas Securities LLC Makes New $1.14 Million Investment in Taysha Gene Therapies, Inc. $TSHA
SG Americas Securities LLC purchased a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the second quarter, according to its most recent filing with the...
MarketBeat·10d ago
News Placeholder
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 2.9% - Here's Why
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 2.9% - Should You Buy...
MarketBeat·13d ago
News Placeholder
Mitsubishi UFJ Asset Management Co. Ltd. Buys New Stake in Taysha Gene Therapies, Inc. $TSHA
Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The...
MarketBeat·16d ago
News Placeholder
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve research firms that are currently covering the company, Marketbeat...
MarketBeat·16d ago
News Placeholder
What is Chardan Capital's Forecast for TSHA FY2025 Earnings?
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Chardan Capital cut their FY2025 earnings estimates for shares of Taysha Gene Therapies in a research report issued on Wednesday, November...
MarketBeat·23d ago
News Placeholder
Taysha Gene Therapies (NASDAQ:TSHA) Downgraded by Wall Street Zen to Sell
Wall Street Zen downgraded Taysha Gene Therapies from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·25d ago
News Placeholder
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 8.5% - Here's What Happened
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 8.5% - Here's What Happened...
MarketBeat·26d ago
News Placeholder
Taysha Gene Therapies' (TSHA) "Buy" Rating Reiterated at Chardan Capital
Chardan Capital restated a "buy" rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday...
MarketBeat·27d ago
News Placeholder
Citizens Jmp Boosts Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00
Citizens Jmp boosted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "market outperform" rating in a report on Wednesday...
MarketBeat·27d ago

Latest TSHA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.